Akeso Presents First Efficacy Data for its PD-1/VEGF Bispecific Antibody Ivonescimab in Treating Metastatic Colorectal Cancer
HONG KONG, Sept. 15, 2024 — Akeso (9926.HK) unveiled the first efficacy data for its proprietary PD-1/VEGF bispecific antibody, ivonescimab, both alone and combined with ligufalimab (anti-CD47 antibody AK117) , in tandem with FOLFOXIRI as a first-line (1L) treatment for metastatic colorectal cancer (mCRC) at the 2024 European Society for Medical…














